Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.62 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467014 | 0.83 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL678162 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL467371 | 0.76 | SIGMAR1 (0.97) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL12648455 | 0.76 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL5804316 | 0.75 | SIGMAR1 (0.93) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL6961777 | 0.72 | SIGMAR1 (0.76) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL9710088 | 0.69 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL5756639 | 0.68 | SIGMAR1 (0.65) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL7401434 | 0.67 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL6795896 | 0.66 | POLB (0.96) | SIGMAR1TP53CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| CN-106456578-B | Use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2020-02-18 | — | — | CN | claimed |
| EP-3104847-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | Mta Támogatott Kutatócsoportok Irodája (HU) | 2016-12-21 | — | — | EP | claimed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | claimed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | claimed |
| EP-4124338-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | Université de Montpellier (FR) | 2023-02-01 | — | — | EP | disclosed |
| US-10842794-B2 | Use of Sigma-1 receptor agonist compounds | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2020-11-24 | — | — | US | disclosed |
| US-10842794-B2 | Use of Sigma-1 receptor agonist compounds | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2020-11-24 | — | — | US | disclosed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | disclosed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | disclosed |
| CN-106456578-B | Use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2020-02-18 | — | — | CN | disclosed |
| US-20190209575-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SigmaDrugs Kft. (HU) | 2019-07-11 | — | — | US | disclosed |
| US-20190209575-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SigmaDrugs Kft. (HU) | 2019-07-11 | — | — | US | disclosed |
| US-10124006-B2 | Use of Sigma-1 receptor agonist compounds | MTA Tämogatott Kutatócsoportok Irodája (HU) | 2018-11-13 | — | — | US | disclosed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | disclosed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | disclosed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | disclosed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10124006-B2 | Use of Sigma-1 receptor agonist compounds | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885TP53 4838/4885CYP1A2 760/4885 |
| US-20190209575-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885TP53 4851/4885CYP1A2 992/4885 |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885TP53 4862/4885CYP1A2 896/4885 |
| US-10842794-B2 | Use of Sigma-1 receptor agonist compounds | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885TP53 4822/4885CYP1A2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.